
Optimizing Data Integrity in Early-Stage Alzheimer’s Clinical Trials
As clinical research shifts toward identifying Alzheimer’s disease at its earliest, asymptomatic stages, the challenge of capturing subtle cognitive changes grows. Industry experts are convening to address how refined scientific strategies, specialized rater training, and flexible eCOA technologies can safeguard endpoint reliability in increasingly complex global study environments.

























